Acentric Research is produced with AI tools under human review. It is affiliated with Acentric Capital, a private investment group whose members may hold positions in companies discussed. The authors are not financial professionals, and nothing here is investment advice or a recommendation to buy or sell any security. AI analysis can be wrong; check every claim against its cited source.
This Brief is an initial scan, not a full investigation. The method and scores behind it are in Biotechnology × Space in the Landscape Report.
Overview
Space offers two things biology cannot get on Earth: long periods of near weightlessness, called microgravity, and conditions that put strain on the human body. Researchers use the first to grow crystals and cells in new ways and to study disease. Others work on the second, to keep astronauts healthy on long missions. In this Brief, biotechnology means biology and medicine that affect human health.
The pair has four Junctions: drug crystals, cells and tissue grown in orbit, disease models built in orbit, and astronaut health technology. What stands out is that most of the work in the sources opened is experiments flown on the International Space Station (ISS), with support from space agencies, the ISS National Laboratory, companies and non-profits. The sources opened name no medicine or therapy made with a crystal or tissue grown in space. The dated sources opened run from 2017 to 2025; the disease-model sources are the oldest (2017 and 2020) and the others are mostly from 2023 to 2025. Later developments were not searched, apart from one newsroom headline from October 2026. [1] ClinicalTrials.gov and FDA records were not searched.
Current state
What each technology does for the other. Space gives biology a changed environment. The ISS National Laboratory says microgravity has been used for more than 30 years to improve the growth of molecular crystals, and that cells form complex three-dimensional structures there. [2] Biology gives space a purpose on Earth: NASA’s Human Research Program says its studies aim to protect astronaut health on long missions to the ISS, the Moon and Mars. [3]
Who is working on it. In the United States, NASA and the ISS National Laboratory sponsor an applied programme for in-space production, which the Laboratory describes as aimed at demonstrating space-based manufacturing that could have an economic impact. [2] In Europe, the European Space Agency runs an accelerator that aims to bring biotechnology, pharmaceutical and cosmetics companies into space-based projects. [4] Redwire, which describes itself as a global space infrastructure and innovation company, flies drug-crystal experiments for pharmaceutical firms. [5] Cedars-Sinai and the National Stem Cell Foundation fly stem-cell and organoid experiments. [6][7]
Four Junctions.
- Microgravity drug crystallization and formulation. Growing crystals of drug molecules in orbit. Company-reported insulin crystals were larger and more ordered than on Earth. See the Junction Brief. [5]
- In-space biomanufacturing. Growing stem cells, organoids and tissue in orbit. Experiments have flown; the aim of making cells or tissue for use on Earth has not been shown in the sources opened. See the Junction Brief. [6][8]
- Microgravity disease models. Using spaceflight as a fast model of bone loss, muscle loss and nerve-cell disease. A 2020 mouse study on the ISS reported protection of muscle and bone. See the Junction Brief. [9]
- Astronaut health technology. Medical technology for crews on long missions; in the sources opened, mostly funded research projects. See the Junction Brief. [3][10]
Who supports the work. The Junctions rest on different sponsors. Redwire’s release thanks NASA and the ISS National Laboratory for support of its drug-crystal flights; it does not give a funding split. [5] Cedars-Sinai says its latest flight was funded through a NASA award in partnership with Axiom Space, which it describes as a company developing space infrastructure, and the National Stem Cell Foundation says a NASA award funds three further missions. [6][7] The disease-model work found was flown by space agencies, including ESA experiments for Italy’s space agency. [11] Astronaut health work is funded by NASA’s Human Research Program and by TRISH. [3][10]
What was left out. One area was considered and excluded: satellite data in public health and telemedicine, a general use of satellite data and links rather than a change to biotechnology. No three-realm candidate was flagged for this pair. [12]
How far it has come. Mostly research flights. Crystals, organoids and mice have been grown or studied on the ISS and returned for analysis; the sources opened report no approved or marketed product that depends on them. [5][6][9]
Opportunities
The ISS National Laboratory says its production programme is meant to bridge the “valley of death” between laboratory research and a successful product or medical treatment. [2] Redwire’s chief scientist describes a way to limit what must fly: send up a thimbleful of crystals, bring them back and use them as seeds to grow more on Earth (a company statement). [13]
Challenges
- Physics and engineering. Flights carry small samples. In 2023 Redwire’s chief scientist said its platform supports 10 experiments at a time, and Cedars-Sinai’s organoids are under 1 millimetre across. [13][6]
- Evidence. Most of the detail comes from the organizations that run the flights, in releases that report plans and expectations more than measured results. The papers behind them were mostly not opened, and the results of the later flights were not searched for. [5][6][7]
- Capital and scale-up. The awards found are about $1.2 million in total for NASA’s 2023 round of eight astronaut-health studies, and $3.1 million from NASA to one foundation for ground research and three missions. [3][7] Results are spread across individual flights, and no registry of them was found.
Data sources
- ISS National Laboratory project portfolio and programme pages, for flight experiments. [14]
- NASA Task Book, for funded astronaut-health projects. [15]
- NIH RePORTER, for federal grants. [16]
- ClinicalTrials.gov, for any study of a drug or tissue linked to a space experiment. [17]
- SEC EDGAR, for company filings and contract announcements. [18]
- No registry of microgravity research outcomes was found; releases and programme pages are the main record.
Changelog
- 2026-11-18: First published.
Sources
- Cedars-Sinai newsroom, headline excerpt “Cedars-Sinai Sends New Stem Cell Experiments to Space”, 2026-10-15, shown in the sidebar of the same page (the release behind that headline was not opened). cedars-sinai.org (accessed 2026-11-18)
- ISS National Laboratory, “In-Space Production Applications” (programme page, undated; statements about the programme and about microgravity research are the Laboratory’s). issnationallab.org (accessed 2026-11-18)
- NASA, “NASA Funds Eight Studies to Protect Astronaut Health on Long Missions”, Human Research Program, 2023-09-29 (agency release). nasa.gov (accessed 2026-11-18)
- European Space Agency, Business and Science Growth Network (BSGN), “Life Sciences Industry Accelerator” (programme page, undated). bsgn.esa.int (accessed 2026-11-18)
- Redwire Corporation, “Redwire Successfully Returns Third Batch of Pharmaceutical Drug Experiments to Earth”, 2024-11-06 (company press release; the results and plans are the company’s). ir.rdw.com (accessed 2026-11-18)
- Cedars-Sinai, “Cedars-Sinai Pioneering Creation of Organoids in Space”, 2025-08-18 (institution release; statements about expected benefits are the investigators’). cedars-sinai.org (accessed 2026-11-18)
- SatNews, “NASA awards National Stem Cell Foundation $3.1 million to continue studying the effects of microgravity on brain cells”, 2025-03-27 (trade site reproducing the foundation’s announcement; statements and claims are the foundation’s). news.satnews.com (accessed 2026-11-18)
- ISS National Laboratory, “ISS National Lab Releases Research Announcement Focused on In-Space Production Applications in Biomanufacturing”, 2021-10-20 (programme release). issnationallab.org (accessed 2026-11-18)
- Amber Dance, “Rodents in space: Keeping bone and muscle strong on the ISS”, ASBMB Today, 2020-09-19 (society magazine reporting a study published in PNAS; the paper itself was not opened). asbmb.org (accessed 2026-11-18)
- Translational Research Institute for Space Health (TRISH), Baylor College of Medicine, “TRISH Research” (programme page, undated; lists projects dated 2017 to 2025; amounts are not stated on the page). bcm.edu(accessed 2026-11-18)
- European Space Agency, “Cells in space”, 2017-12-07 (archive article). esa.int (accessed 2026-11-18)
- Acentric Research, “Landscape Report, November 2026”, exclusions. acentricresearch.com (accessed 2026-11-18)
- Manufacturing Chemist, “Redwire’s Lab-in-a-Box aims to leverage the ISS National Lab to improve drug manufacturing” (trade article, published 2023-11-17; it describes the SpaceX CRS-29 launch; statements by the company’s chief scientist are the company’s). manufacturingchemist.com (accessed 2026-11-18)
- ISS National Laboratory, research project portfolio. issnationallab.org (listed as a data source; the portfolio itself was not opened for this Brief)
- NASA Task Book, research project records. taskbook.nasaprs.com (named on the TRISH page as the record of its projects; listed as a data source, not opened for this Brief)
- NIH RePORTER, project search. reporter.nih.gov (listed as a data source; not opened for this Brief)
- ClinicalTrials.gov, study search. clinicaltrials.gov (listed as a data source; not searched for this Brief)
- SEC EDGAR, full-text search. sec.gov (listed as a data source; not run for this Brief)